Department of Pathobiology, Texas A&M College of Veterinary Medicine and Biomedical Sciences, College Station, Texas, USA.
Am J Perinatol. 2012 Nov;29(10):777-85. doi: 10.1055/s-0032-1316447. Epub 2012 Jul 16.
The purpose of this review is to provide information detailing the existing evidence with regard to the hypothesis that marinobufagenin (MBG) is an important etiologic and predictive factor in preeclampsia (PE). In addition, evidence describing the role of the antagonist to MBG, resibufogenin (RBG), in the prevention and/or treatment of this disorder is provided.
The studies outlined were performed in an animal model of PE, in in vitro experiments, and in human studies.
Data have been obtained that strongly support the hypothesis that ~60 to 70% of PE patients demonstrate elevations in urinary and serum MBG levels. In the animal model, the entire syndrome can be prevented by the administration of RBG beginning early in pregnancy.
Expanded human trials of MBG as a predictor of the later development of PE are warranted as are studies of the efficacy and safety of RBG as a preventative/therapy.
本综述旨在提供详细信息，阐述马兜铃酸（MBG）是先兆子痫（PE）重要病因和预测因素这一假说的现有证据。此外，还提供了描述 MBG 拮抗剂瑞马兜铃酸（RBG）在预防和/或治疗这种疾病中的作用的证据。
概述的研究是在 PE 的动物模型中、在体外实验中和在人类研究中进行的。
已获得的数据强烈支持以下假说，即 60%至 70%的 PE 患者尿液和血清 MBG 水平升高。在动物模型中，从妊娠早期开始给予 RBG 可预防整个综合征。
有必要进行更多的人类 MBG 作为 PE 后期发展预测因子的试验，以及研究 RBG 作为预防/治疗药物的疗效和安全性的试验。
